This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignees: Inozyme Pharma, Inc., Westfaelische Wilhelms-Universitaet Muenster. Active years: 2022.
Company Filing History:
1 out of 4 
1 out of 19 Years Active: 2022
Title: Frank Rutsch: Innovator in Myointimal Proliferation Treatment
Introduction
Frank Rutsch is a notable inventor based in Münster, Germany. He has made significant contributions to the field of medical treatments, particularly in addressing myointimal proliferation. His innovative approach has led to the development of a unique patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Frank Rutsch holds a patent for "Methods of treating myointimal proliferation." This invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment, or fusion protein thereof. This patent reflects his commitment to finding effective solutions for complex medical issues.
Career Highlights
Throughout his career, Frank Rutsch has worked with prominent organizations, including Inozyme Pharma, Inc. and Westfälische Wilhelms-Universität Münster. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Frank has collaborated with talented individuals such as Yan Yan and Anumeha Shah. These partnerships have enriched his work and fostered an environment of innovation and creativity.
Conclusion
Frank Rutsch is a distinguished inventor whose work in treating myointimal proliferation has the potential to make a significant impact in the medical field. His dedication to innovation and collaboration continues to drive advancements in healthcare.